Discontinued — last reported Q4 '25
Charges associated with convertible senior notes
Over 3 years (FY 2022 to FY 2025), Charges associated with convertible senior notes shows a downward trend with a -100.0% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
How to read this metric
Higher charges indicate a higher cost of debt or significant financing activity, which can impact net income.
Detailed definition
Charges associated with convertible senior notes represent the non-cash or cash costs related to the company's debt fina...
Peer comparison
Specific to companies with complex capital structures; peers with similar debt profiles will report comparable financing costs.
other_income_expense_charges_associated_with_convertible_549661Historical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $17.50M | $17.50M | $17.50M | $17.50M | $0.00 | $0.00 | $0.00 | $0.00 | $88.70M | $49.70M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -100.0% | — | — | — | — | -44.0% | -100.0% | — | — | — | — | — |
| YoY Change | — | — | — | — | -100.0% | -100.0% | -100.0% | -100.0% | — | — | — | — | -100.0% | -100.0% | — | — |
Business Segments
| Segment | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 |
|---|---|---|---|---|---|---|---|---|
| Reportable Segment | $88.70M | $49.70M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total | $88.70M | $49.70M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Reportable Segment was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.
Charges associated with convertible senior notes at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's charges associated with convertible senior notes?
- Neurocrine Biosciences (NBIX) reported charges associated with convertible senior notes of $0.00 in Q4 2025.
- What is the long-term trend for Neurocrine Biosciences's charges associated with convertible senior notes?
- Over 3 years (2022 to 2025), Neurocrine Biosciences's charges associated with convertible senior notes has grown at a -100.0% compound annual growth rate (CAGR), from $70.00M to $0.00.
- What does charges associated with convertible senior notes mean?
- Costs related to the company's convertible debt financing.